Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company that specializes in the research, cultivation, manufacturing, and supply of cannabis-based medicines. Founded in 2018 following the legalization of medicinal cannabis, Celadon was among the first companies to obtain Home Office and MHRA licenses for the production of high-THC medicines. In a significant development for the industry, the company listed on the AIM market of the London Stock Exchange in March 2022, marking a major milestone following GW Pharma's acquisition. With a focus on enhancing the quality of life for patients in need, particularly the 8 million chronic pain sufferers in the UK, Celadon operates a 100,000 sq ft facility in the UK, which includes hydroponic cultivation areas, proprietary extraction and GMP standard API manufacturing, as well as an R&D and testing laboratory. This infrastructure is estimated to require over £60m and 2-3 years for a new market entrant to replicate. The company's subsidiary, LVL Health, is conducting a conditionally approved clinical trial using cannabis-based medicines to address chronic pain in the UK. Additionally, Celadon holds a 20% stake in Kingdom Therapeutics, an early-stage biopharma company that has developed a licensed cannabinoid medicine for children with Autism Spectrum Disorder. This involvement forms a part of Celadon's 'Breakthrough R&D' program, which focuses on developing novel IP and the future of cannabis-based medicines. For more information about Celadon Pharmaceuticals Plc, visit www.celadonpharma.com.